Asset Details
Do you wish to reserve the book?
Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
Do you wish to request the book?
Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
2023
Overview
Clinical and demographic data, including, age, sex, disease duration, body mass index (BMI), pain, patient's global assessment, physician's global assessment, Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, and Maastricht Enthesitis Score, were recorded. Additionally, the presence of comorbid conditions with SpA may decrease the tolerability of medications and indeed may influence the decision to use biological drugs.3 The extraarticular manifestations and comorbidities of SpA patients were found to increase disability and healthcare expenditures.4 The association of SpA with comorbid situations were previously evaluated.5\"8 Some of the recommendations/guidelines underline the importance of considering comorbid situations during the management of SpA.910 The main objective of this study was to evaluate the comorbid conditions of Turkish patients with SpA. The questionnaire contains questions about hypertension (HT), diabetes mellitus (DM) (including any complication related to DM), renal disease, chronic lung diseases (asthma or chronic obstructive pulmonary disease), pulmonary circulation disorders, thyroid dysfunction (hypo-or hyperthyroidism, any thyroid surgery, and consuming thyroid hormone replacement or suppressing medicine), cardiovascular system disorders (coronary artery disease, myocardial infarction, congestive heart failure, peripheral vascular events, and cardiac valve disease) gastrointestinal (GI) system disorders (peptic ulcer and GI bleeding), hepatic disorders, history of cancer, neurologic disorders (stroke, dementia, atlantoaxial instability, and spinal cord injury/cauda equina syndrome), psychiatric disorders (depression/psychosis). Three or more groups were compared by the Kruskal-Wallis test or analysis of variance (ANOVA) depending on their distribution.
